ALNY — Alnylam Pharmaceuticals, Inc.
Is ALNY overbought or oversold? Here is the current MarketMoodz read.
Alnylam Pharmaceuticals, Inc. (ALNY) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $156.50. The rating moved from Oversold to Neutral on November 12, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$156.50
- Last changeMoved from Oversold to Neutral on November 12, 2026
- SectorHealthcare
- IndustryBiotechnology
AI analysis
Alnylam presents a compelling mix of commercial revenue and a differentiated RNAi platform with multiple assets in market or late development. Steady sector flows into large‑cap pharma and recent market calm provide a constructive near‑term backdrop. Primary strengths include diversified product sales, strategic partnerships that extend reach, and a balance sheet that has historically supported the transition from R&D to commercialization. Key near‑term upside catalysts include quarterly results, commercial uptake metrics, and favorable regulatory readouts; downside scenarios center on clinical/regulatory setbacks, reimbursement headwinds driven by tighter Medicare integrity measures, and execution issues in manufacturing or partner launches. Social and filings activity are currently neutral, implying limited market re‑pricing absent new data or news.
Key factors
- Proven RNAi platform with multiple commercial therapies contributing recurring revenue and strong long‑term IP position
- Diversified product portfolio and strategic partnerships that expand commercialization reach and reduce single‑asset concentration risk
- Favorable sector flows into large‑cap pharma and defensive healthcare exposure supporting relative outperformance in volatile markets
- Conservative near‑term market environment with limited macro surprises, reducing downside from abrupt risk‑off moves
- Cash runway and historical ability to transition from development to commercial scale, supporting continued investment in pipeline
- Potential near‑term catalysts from earnings, product uptake data, or regulatory updates that could re‑rate shares
Risks
- Clinical or regulatory setbacks on late‑stage pipeline assets that could materially impact future revenue expectations
- Pricing and reimbursement pressure, including Medicare/Medicare Advantage regulatory tightening that could affect net pricing or access
- Intensifying competition in relevant therapeutic areas and potential biosimilar or novel modality entrants
- Manufacturing or supply chain disruptions that could constrain commercial product shipments
- Investor sentiment volatility in biotech names leading to outsized share‑price moves independent of fundamentals
- Counterparty or partnership execution risk that could delay launches or revenue recognition
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for ALNY — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.